3681 Stock Overview
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
SinoMab BioScience Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.16 |
| 52 Week High | HK$1.95 |
| 52 Week Low | HK$1.00 |
| Beta | 0.69 |
| 11 Month Change | -16.55% |
| 3 Month Change | -25.64% |
| 1 Year Change | 0.87% |
| 33 Year Change | -61.07% |
| 5 Year Change | -74.84% |
| Change since IPO | -80.67% |
Recent News & Updates
Recent updates
Update: SinoMab BioScience (HKG:3681) Stock Gained 21% In The Last Year
Mar 04
What You Need To Know About SinoMab BioScience Limited's (HKG:3681) Investor Composition
Jan 28Did SinoMab BioScience Limited (HKG:3681) Insiders Buy Up More Shares?
Jan 01
Loss-Making SinoMab BioScience Limited (HKG:3681) Expected To Breakeven In The Medium-Term
Nov 30Shareholder Returns
| 3681 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -4.9% | -4.8% | -5.3% |
| 1Y | 0.9% | -14.6% | 11.3% |
Return vs Industry: 3681 exceeded the Hong Kong Biotechs industry which returned -12.5% over the past year.
Return vs Market: 3681 underperformed the Hong Kong Market which returned 9.5% over the past year.
Price Volatility
| 3681 volatility | |
|---|---|
| 3681 Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 3681 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 3681's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 214 | Shawn Leung | www.sinomab.com |
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. Its product pipeline comprises SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA); is in phase II clinical trial to treat non-Hodgkin’s lymphoma and systemic lupus erythematosus; and is in phase I clinical trial to treat alzheimer’s disease and sjogren’s syndrome. It also develops SM17, a humanized anti-IL-25 receptor, which is in phase I clinical trial to treat asthma and atopic dermatitis, as well as in preclinical trial to treat idiopathic pulmonary fibrosis; and SN1011, a Bruton’s tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, neuromyelitis optica spectrum disorder, and multiple sclerosis, as well as in phase 1 clinical trial to treat systemic lupus erythematosus.
SinoMab BioScience Limited Fundamentals Summary
| 3681 fundamental statistics | |
|---|---|
| Market cap | HK$1.27b |
| Earnings (TTM) | -HK$215.02m |
| Revenue (TTM) | HK$2.16m |
586.7x
P/S Ratio-5.9x
P/E RatioIs 3681 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3681 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.00m |
| Cost of Revenue | CN¥1.48m |
| Gross Profit | CN¥521.00k |
| Other Expenses | CN¥200.16m |
| Earnings | -CN¥199.64m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 26.00% |
| Net Profit Margin | -9,961.93% |
| Debt/Equity Ratio | 153.0% |
How did 3681 perform over the long term?
See historical performance and comparison